NLS SymCel

The company is expanding to bring its technology to the clinical antimicrobial susceptibility testing (AST) markets. The company is currently commercially leveraging the Horizon 2020 funded Phase II (AST) project – in which multi-resistant bacterial infections will be clinically validated using Symcel’s screening method. “Our business development strategy has evolved and is now twofold: we […]

Symcel has secured €3.572 million Horizon 2020 funding to support the company’s evaluation of improved combination testing of antibiotics against extensively drug-resistant bacteria in sepsis patients. The project runs over 28 months with a consortium of academic and clinical opinion leaders from Karolinska Institutet, Hospital Universitario Ramón y Cajal, Careggi University Hospital, Rigshospitalet, IHE and […]

Symcel Sweden has announced the appointment of Jesper Ericsson as new Chief Executive Officer – succeeding Christer Wallin who is now retiring. ”I very much look forward to developing the plan and globally establishing Symcel’s solutions for phenotypic screening – with a substantial focus on sales and marketing in the coming years,” said Jesper Ericsson. Jesper […]

Symcel has partnered with TiKa Diagnostics and St. George’s University of London, for the use of its microcalorimetry technology in testing mycobacteria and for antimicrobial peptide (AMP) studies. The project between Symcel and TiKa Diagnostics, a spin-out from St. George’s University of London, has the potential to enable rapid Mtb culture confirmation, reducing detection time […]

SymCel’s calScreener™ technology is going in nine locations across five different countries in a mixture of university institutions and pharmaceutical companies. The nine include four signings in Sweden, two signings in Switzerland, and one each in Holland, South Africa, Germany and South East Asia Scientific data published in The Biotechnology Journal shows that CalScreener’s isothermal microcalorimetry label free […]